<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00467142</url>
  </required_header>
  <id_info>
    <org_study_id>CDR0000540522</org_study_id>
    <secondary_id>IB-2006-31</secondary_id>
    <secondary_id>IB-OMEGA</secondary_id>
    <secondary_id>INCA-RECF0387</secondary_id>
    <secondary_id>EUDRACT-2006-003901-22</secondary_id>
    <nct_id>NCT00467142</nct_id>
  </id_info>
  <brief_title>Bevacizumab and Combination Chemotherapy as First-Line Therapy in Treating Patients With Metastatic Colorectal Cancer That Cannot Be Removed by Surgery</brief_title>
  <official_title>Phase II Study Evaluating the Efficacy and Tolerance to Chemotherapy With 5-fluorouracil, Folinic Acid, Irinotecan and Bevacizumab as First-line Treatment in Patients With Metastatic Colorectal Cancer</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Institut Bergonié</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>National Cancer Institute (NCI)</source>
  <brief_summary>
    <textblock>
      RATIONALE: Monoclonal antibodies, such as bevacizumab, can block tumor growth in different&#xD;
      ways. Some block the ability of tumor cells to grow and spread. Others find tumor cells and&#xD;
      help kill them or carry tumor-killing substances to them. Bevacizumab may also stop the&#xD;
      growth of colorectal cancer by blocking blood flow to the tumor. Drugs used in chemotherapy,&#xD;
      such as irinotecan, leucovorin, and fluorouracil, work in different ways to stop the growth&#xD;
      of tumor cells, either by killing the cells or by stopping them from dividing. Giving&#xD;
      bevacizumab together with combination chemotherapy may kill more tumor cells.&#xD;
&#xD;
      PURPOSE: This phase II trial is studying how well giving bevacizumab together with&#xD;
      combination chemotherapy works as first-line therapy in treating patients with metastatic&#xD;
      colorectal cancer that cannot be removed by surgery.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      OBJECTIVES:&#xD;
&#xD;
      Primary&#xD;
&#xD;
        -  Determine the efficacy of bevacizumab, irinotecan hydrochloride, leucovorin calcium, and&#xD;
           fluorouracil, in terms of partial or complete response, in patients with unresectable&#xD;
           metastatic colorectal cancer.&#xD;
&#xD;
      Secondary&#xD;
&#xD;
        -  Determine the duration of response in patients treated with this regimen.&#xD;
&#xD;
        -  Determine the overall survival and progression-free survival of patients treated with&#xD;
           this regimen.&#xD;
&#xD;
        -  Determine the tolerability of this regimen in these patients.&#xD;
&#xD;
        -  Assess the pharmacogenetics and change in genetic polymorphisms susceptible to&#xD;
           modification by this regimen.&#xD;
&#xD;
      OUTLINE: This is a nonrandomized, multicenter study.&#xD;
&#xD;
      Patients receive irinotecan hydrochloride IV over 90 minutes, leucovorin calcium IV over 2&#xD;
      hours, and bevacizumab IV on day 1. Patients also receive fluorouracil IV over 46 hours&#xD;
      beginning on day 1. Treatment repeats every 2 weeks in the absence of disease progression or&#xD;
      unacceptable toxicity.&#xD;
&#xD;
      Blood and tissue samples are collected periodically for pharmacogenetic and genetic&#xD;
      polymorphism analysis.&#xD;
&#xD;
      PROJECTED ACCRUAL: A total of 61 patients will be accrued for this study.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date>January 2007</start_date>
  <primary_completion_date type="Actual">May 2011</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Non-Randomized</allocation>
    <primary_purpose>Treatment</primary_purpose>
  </study_design_info>
  <primary_outcome>
    <measure>Partial or complete response rate</measure>
  </primary_outcome>
  <secondary_outcome>
    <measure>Duration of response</measure>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Overall and progression-free survival</measure>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Tolerance to treatment</measure>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Modified genetic polymorphisms and pharmacogenetics</measure>
  </secondary_outcome>
  <enrollment type="Anticipated">61</enrollment>
  <condition>Colorectal Cancer</condition>
  <intervention>
    <intervention_type>Biological</intervention_type>
    <intervention_name>bevacizumab</intervention_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>fluorouracil</intervention_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>irinotecan hydrochloride</intervention_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>leucovorin calcium</intervention_name>
  </intervention>
  <intervention>
    <intervention_type>Genetic</intervention_type>
    <intervention_name>polymorphism analysis</intervention_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        DISEASE CHARACTERISTICS:&#xD;
&#xD;
          -  Histologically confirmed adenocarcinoma of the colon or rectum&#xD;
&#xD;
               -  No other histological types&#xD;
&#xD;
          -  Metastatic, unresectable disease&#xD;
&#xD;
               -  No bone metastases only&#xD;
&#xD;
          -  Unidimensionally measurable metastatic disease&#xD;
&#xD;
          -  No CNS metastases&#xD;
&#xD;
        PATIENT CHARACTERISTICS:&#xD;
&#xD;
          -  WHO performance status (PS) 0-2 OR Karnofsky PS 70-100%&#xD;
&#xD;
          -  Life expectancy ≥ 12 weeks&#xD;
&#xD;
          -  ANC &gt; 1,500/mm³&#xD;
&#xD;
          -  Platelet count ≥ 100,000/mm³&#xD;
&#xD;
          -  Hemoglobin ≥ 10 g/dL&#xD;
&#xD;
          -  Bilirubin ≤ 1.25 times normal (1.5 times normal in presence of hepatic metastases)&#xD;
&#xD;
          -  AST and ALT &lt; 3 times normal (5 times normal in presence of hepatic metastases)&#xD;
&#xD;
          -  Creatinine &lt; 1.25 times normal&#xD;
&#xD;
          -  No proteinuria&#xD;
&#xD;
          -  Not pregnant or nursing&#xD;
&#xD;
          -  Negative pregnancy test&#xD;
&#xD;
          -  Fertile patients must use effective contraception&#xD;
&#xD;
          -  No other cancer in the past 5 years except for carcinoma in situ of the uterine cervix&#xD;
             or basal cell skin cancer&#xD;
&#xD;
          -  No hypersensitivity to fluorouracil&#xD;
&#xD;
          -  No hypersensitivity to leucovorin calcium, bevacizumab, or their excipients&#xD;
&#xD;
          -  No hypersensitivity to Chinese hamster ovarian cell products or other recombinant&#xD;
             humanized or nonhumanized monoclonal antibodies&#xD;
&#xD;
          -  No allergy to irinotecan hydrochloride&#xD;
&#xD;
          -  No prior reaction to attenuated vaccines (fever, jaundice)&#xD;
&#xD;
          -  No poor nutritional status&#xD;
&#xD;
          -  No Biermer anemia or other anemia due to vitamin B12 deficiency&#xD;
&#xD;
          -  No uncontrolled symptomatic occlusion or subocclusion&#xD;
&#xD;
          -  No medullary hypoplasia or severe insufficiency&#xD;
&#xD;
          -  No prior chronic intestinal disease&#xD;
&#xD;
          -  No Gilbert's syndrome&#xD;
&#xD;
          -  No intra-abdominal inflammatory reaction (e.g., gastroduodenal ulcer, diverticulitis,&#xD;
             or colitis)&#xD;
&#xD;
          -  No chronic intestinal inflammatory disease&#xD;
&#xD;
          -  No thromboembolic arterial condition in the past 6 months, including any of the&#xD;
             following:&#xD;
&#xD;
               -  Cardiovascular accident&#xD;
&#xD;
               -  Transient ischemic attack&#xD;
&#xD;
               -  Myocardial infarction&#xD;
&#xD;
          -  No infection or serious noncancerous disease&#xD;
&#xD;
          -  No condition that is unstable or would increase risk to the patient, including any of&#xD;
             the following:&#xD;
&#xD;
               -  Unstable angina&#xD;
&#xD;
               -  Poorly controlled hypertension&#xD;
&#xD;
               -  Severe cardiac insufficiency&#xD;
&#xD;
               -  Serious arrhythmia&#xD;
&#xD;
               -  Bleeding diathesis&#xD;
&#xD;
               -  Pulmonary disease at risk of decompensation&#xD;
&#xD;
          -  No familial, geographical, social, or psychological condition that would preclude&#xD;
             study participation&#xD;
&#xD;
          -  No prisoners or patients without guardians&#xD;
&#xD;
        PRIOR CONCURRENT THERAPY:&#xD;
&#xD;
          -  At least 8 weeks since prior surgery&#xD;
&#xD;
          -  At least 6 months since prior adjuvant chemotherapy&#xD;
&#xD;
          -  At least 1 month since prior palliative chemotherapy&#xD;
&#xD;
          -  No prior abdominal or pelvic radiotherapy&#xD;
&#xD;
          -  At least 30 days since prior participation in another investigational study&#xD;
&#xD;
          -  No prior bevacizumab&#xD;
&#xD;
          -  No extensive intestinal resection (e.g., partial colectomy or extensive thin&#xD;
             resection)&#xD;
&#xD;
          -  No concurrent warfarin, Hypericum perforatum (St. John's wort), or prophylactic&#xD;
             phenytoin&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Yves Becouarn, MD</last_name>
    <role>Study Chair</role>
    <affiliation>Institut Bergonié</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Institut Bergonie</name>
      <address>
        <city>Bordeaux</city>
        <zip>33076</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>France</country>
  </location_countries>
  <verification_date>July 2009</verification_date>
  <study_first_submitted>April 25, 2007</study_first_submitted>
  <study_first_submitted_qc>April 25, 2007</study_first_submitted_qc>
  <study_first_posted type="Estimate">April 27, 2007</study_first_posted>
  <last_update_submitted>May 13, 2011</last_update_submitted>
  <last_update_submitted_qc>May 13, 2011</last_update_submitted_qc>
  <last_update_posted type="Estimate">May 16, 2011</last_update_posted>
  <keyword>stage IV colon cancer</keyword>
  <keyword>stage IV rectal cancer</keyword>
  <keyword>adenocarcinoma of the colon</keyword>
  <keyword>adenocarcinoma of the rectum</keyword>
  <keyword>recurrent colon cancer</keyword>
  <keyword>recurrent rectal cancer</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Colorectal Neoplasms</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Leucovorin</mesh_term>
    <mesh_term>Bevacizumab</mesh_term>
    <mesh_term>Fluorouracil</mesh_term>
    <mesh_term>Irinotecan</mesh_term>
    <mesh_term>Calcium</mesh_term>
    <mesh_term>Levoleucovorin</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

